Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Markets

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton May 21, 2021 7:25pm

344 Views

Post# 33252829

RE:RE:RE:RE:RE:RE:RE:RE:Markets

Mugs
I count min of 7 years in USA per their corp presenation and assuming they do the math correctly on FDA NDA / commercilaization. Start in full year 2025 thru to 2031, loss exclusivity in 2032.
Phase 3 completes end of 2022 early 2022 Q1/Q2 leaves 2.5 years for them to get FDA approval (their slated 2025 start). A BP could get their quicker 9results of PH3/package, submission etc).

https://antibethera.com/wp-content/uploads/2021/04/Antibe-Corporate-Presentation-April-2021.pdf

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale